评估自体RAK细胞在无法手术切除且≥1线全身治疗失败的转移性肾癌患者中安全性和初步临床疗效的Ⅰ期临床试验
[Translation] A phase I clinical trial to evaluate the safety and preliminary clinical efficacy of autologous RAK cells in patients with metastatic renal cell carcinoma who were unresectable and failed ≥1 line of systemic therapy
1、评估无法手术切除且≥1线全身治疗失败的转移性肾癌患者对自体RAK细胞治疗的安全性和耐受性,探索最大耐受剂量; 2、推荐自体RAK细胞回输治疗的后续临床试验输注剂量和方案。 3、探索自体RAK细胞的免疫学机制和效应原理。
[Translation] 1. Evaluate the safety and tolerability of autologous RAK cell therapy in patients with metastatic renal cancer who cannot be resectable and have failed ≥1 line of systemic therapy, and explore the maximum tolerated dose; 2. Recommend follow-up clinical trials for autologous RAK cell reinfusion therapy Trial infusion dose and schedule. 3. To explore the immunological mechanism and effect principle of autologous RAK cells.
100 Clinical Results associated with TaKaRa Biomedical Technology(Beijing) Co., Ltd.
0 Patents (Medical) associated with TaKaRa Biomedical Technology(Beijing) Co., Ltd.
100 Deals associated with TaKaRa Biomedical Technology(Beijing) Co., Ltd.
100 Translational Medicine associated with TaKaRa Biomedical Technology(Beijing) Co., Ltd.